Position in TBPH
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$733,790
+$309,448 QoQ
Shares Held
45,212
+99.3% QoQ
Ownership
0.088%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TBPH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Gotham Asset Management, LLC holds $372,259,160 across 45 Biotechnology names. TBPH ranks #27 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
82,846 | $64,010,133 | |
| 2 | INCY |
Incyte Corp
|
676,670 | $63,688,180 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
746,841 | $48,268,333 | |
| 4 | EXEL |
Exelixis, Inc.
|
919,870 | $39,453,224 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
1,416,091 | $39,225,720 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
91,626 | $17,321,895 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
43,710 | $14,462,327 | |
| 8 | CAI |
Caris Life Sciences, Inc.
|
744,426 | $13,310,336 |
All Filings in TBPH
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $733,790 | 45,212 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $424,342 | 22,680 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||